Heart failure & cardiomyopathies
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF
Authors' conclusion
Sacubitril/valsartan significantly reduced the risk of HF events and improved health status across the LSS spectrum in HFrEF and HFmrEF/HFpEF.
Study context
- Population
- Patients with HFrEF and HFmrEF/HFpEF, by EQ-5D-3L Level Sum Score (LSS) tertiles12,974 with baseline LSS
- Participants
- 13,195 patients
- Comparison
- Sacubitril/valsartan vs enalapril or valsartan
- Primary endpoint
- First heart failure (HF) hospitalization or CV death, by LSS tertile
Methodological detailspooled patient-level analysis
- Pooled patient-level analysis
Primary result
As reported in the abstract
First HF hospitalization or CV death, by baseline LSS tertile (subgroups)
Sacubitril/valsartan vs Enalapril or valsartanHazard ratio (95% CI)
T1
0.87(0.75–1.00)
T2
0.80(0.71–0.90)
T3
0.87(0.77–0.97)
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Change in LSS severity (improvement vs worsening) · 8 monthsOrdinal logistic regression | 1.16 (1.08–1.24) | |
| 0.512Odds ratio (log scale) |
Baseline LSS and risk of primary endpoint
- Higher LSS independently associated with greater risk of the primary endpoint
Original publication
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. Eur Heart J Cardiovasc Pharmacother. Published 21 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it